Company to host conference call March 16, 2023, at 4:30 PM EDT SEATTLE, Wash and VANCOUVER, British Columbia, Mar. 16, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and…
/Read More
Topline Data Expected in 2Q 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, March 8, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject enrolled…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, March 3, 2023 (GLOBE NEWSWIRE) —Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced data from the Phase 3 ORCA-2 trial will be presented at the Society for Research on Nicotine…
/Read More
SEATTLE, WA and VANCOUVER, British Columbia, March 2, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2022 financial results and provide an update…
/Read More
Topline Data Expected in 2Q 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 7, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial…
/Read More